The "Pharmaceutical Dissolution Market - A Global and Regional Analysis: Focus on Type, End User, and Region - Analysis and Forecast, 2024-2033" has been added to ResearchAndMarkets.com's offering.

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026New preclinical data demonstrated SIL204’s ...

Goldman Sachs top picks include includes blue-chip names such as Reliance Industries, NTPC, Titan Company, InterGlobe ...

Analysts believe the company is well-positioned for "sustained, high-quality growth," reinforcing long-term earnings visibility ...

Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and ...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell ...

Our Bureau, Bengaluru Wednesday, November 12, 2025, 13:30 Hrs [IST] ...